Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEPENTHE
2024-519129-38-00Phase 2Authorised
- Sponsor
- Istituti Clinici Scientifici Maugeri
- Start
- Jan 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, single-arm trial of pembrolizumab in thyroid cancer, well-differentiated thyroid cancer (WDTC), poorly differentiated thyroid carcinoma (PDTC) and 1 more, sponsored by Istituti Clinici Scientifici Maugeri. Planned start Jan 2025; status: authorised.
02
Drugs
03
Conditions
thyroid cancerwell-differentiated thyroid cancer (WDTC)poorly differentiated thyroid carcinoma (PDTC)oncocytic carcinoma
Beyond the preview
Go deeper on 2024-519129-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519129-38-00.